Citadel Advisors’s PRA Health Sciences, Inc. PRAH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-572,994
| Closed | -$94.7M | – | 15363 |
|
|
2021
Q2 | $94.7M | Buy |
572,994
+419,931
| +274% | +$70.1M | 0.02% | 701 |
|
|
2021
Q1 | $23.5M | Buy |
153,063
+146,613
| +2,273% | +$19.9M | 0.01% | 1766 |
|
|
2020
Q4 | $809K | Buy |
+6,450
| New | +$721K | ﹤0.01% | 7237 |
|
|
2020
Q3 | – | Sell |
-38,250
| Closed | -$3.9M | – | 11055 |
|
|
2020
Q2 | $3.72M | Sell |
38,250
-426,832
| -92% | -$39.7M | ﹤0.01% | 3514 |
|
|
2020
Q1 | $38.6M | Sell |
465,082
-96,547
| -17% | -$9.42M | 0.02% | 772 |
|
|
2019
Q4 | $62.4M | Sell |
561,629
-629,409
| -53% | -$64.7M | 0.03% | 650 |
|
|
2019
Q3 | $118M | Buy |
1,191,038
+1,183,524
| +15,751% | +$118M | 0.06% | 334 |
|
|
2019
Q2 | $745K | Sell |
7,514
-375,301
| -98% | -$35.8M | ﹤0.01% | 6184 |
|
|
2019
Q1 | $42.2M | Buy |
382,815
+375,961
| +5,485% | +$39.3M | 0.02% | 790 |
|
|
2018
Q4 | $631K | Sell |
6,854
-144,435
| -95% | -$14.6M | ﹤0.01% | 6043 |
|
|
2018
Q3 | $16.7M | Buy |
151,289
+146,744
| +3,229% | +$15.3M | 0.01% | 1563 |
|
|
2018
Q2 | $424K | Sell |
4,545
-842
| -16% | -$72.5K | ﹤0.01% | 6648 |
|
|
2018
Q1 | $447K | Sell |
5,387
-74,623
| -93% | -$6.63M | ﹤0.01% | 6087 |
|
|
2017
Q4 | $7.29M | Sell |
80,010
-587,330
| -88% | -$48.9M | ﹤0.01% | 2045 |
|
|
2017
Q3 | $50.8M | Buy |
667,340
+456,851
| +217% | +$34.5M | 0.04% | 542 |
|
|
2017
Q2 | $15.8M | Sell |
210,489
-55,341
| -21% | -$3.84M | 0.01% | 1135 |
|
|
2017
Q1 | $17.3M | Buy |
265,830
+166,577
| +168% | +$9.81M | 0.02% | 1061 |
|
|
2016
Q4 | $5.47M | Sell |
99,253
-8,909
| -8% | -$489K | 0.01% | 1909 |
|
|
2016
Q3 | $6.11M | Sell |
108,162
-630
| -0.6% | -$30.9K | 0.01% | 1781 |
|
|
2016
Q2 | $4.54M | Buy |
108,792
+4,828
| +5% | +$222K | 0.01% | 1900 |
|
|
2016
Q1 | $4.45M | Buy |
+103,964
| New | +$4.39M | 0.01% | 1878 |
|
|
2015
Q3 | – | Sell |
-14,755
| Closed | -$536K | – | 9381 |
|
|
2015
Q2 | $536K | Sell |
14,755
-67,303
| -82% | -$2.13M | ﹤0.01% | 4853 |
|
|
2015
Q1 | $2.37M | Buy |
+82,058
| New | +$2.29M | ﹤0.01% | 2860 |
|
Other funds holding PRAH
Citadel Advisors's PRAH Position: Q3 2021 in Review
Citadel Advisors sold out of PRA Health Sciences, Inc. (PRAH) in Q3 2021, closing a stake of 572,994 shares — an estimated $94.7M sold.
Citadel Advisors first reported a position in PRAH in Q1 2015 and held it in 23 quarters. The position peaked at $118M in Q3 2019. 1 fund tracked by Wall St. Rank holds PRAH as of Q3 2021.
- Citadel Advisors reported no remaining PRA Health Sciences, Inc. position as of Q3 2021 after selling out during the quarter.
- Citadel Advisors sold 572,994 PRA Health Sciences, Inc. shares in Q3 2021, an estimated $94.7M.
- Citadel Advisors first reported a position in PRA Health Sciences, Inc. in Q1 2015 and held it in 23 quarters.
- Citadel Advisors's PRA Health Sciences, Inc. position peaked at $118M in Q3 2019.
- 1 fund tracked by Wall St. Rank held PRA Health Sciences, Inc. as of Q3 2021.
Based on Citadel Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.